Ex vivo Optimization of Glucose-Regulated Protein 94/Glycoprotein 96 Expressions in Mammospheres; Implication for Breast Cancer Immunotherapy

Document Type : Original Article

Authors

1 Department of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran

2 Department of Stem cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran, Iran

3 Department of Surgery, Emam Khomeini General Hospital, Urmia, Iran

Abstract

Objective: The induction of immunity against cancer stem cells (CSCs) can boost the efficiency of cancer vaccines. Heat shock proteins (HSPs) are required for the successful activation of anti-tumor immune responses. Glycoprotein 96 (gp96) is a well-known HSP that promotes the cross-presentation of tumor antigens. The aim of the present study was to optimize the temperature for induction of gp96 in grade 3 breast cancer spheres.
Materials and Methods: In the experimental study, CSCs were enriched from breast tumor tissue samples and cultured in DMEM-F12 with epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), B27, and bovine serum albumin (BSA) for 22 days. The expression level of CD24 and CD44 as CSC markers was measured by flow cytometry in secondary mammospheres, and the expression of NANOG, SOX2, and OCT4 genes in CSCs was also analyzed using the real-time polymerase chain reaction (PCR). To find the optimal temperature regulation of gp96, the mammosphere was incubated at different temperatures for 1 hour, and gp96 expression was measured using the western blotting assay.
Results: Primary mammospheres were obtained after seven days of culture, and secondary spheres formed 22 days after passage. Flow cytometry analysis showed that cells with CD24- CD44+ phenotype were enriched in the culture period (from 2.6% on day 1 to 32.6% on day 22). Real-time PCR indicated that OCT4, NANOG, and SOX2 expression in mammospheres were increased by 3.8 ± 0.6, 17.8 ± 0.6, and 7.7 ± 0.8 fold respectively in comparison to the MCF-7 cell line. Western blot analysis showed that gp96 production was significantly upregulated when mammospheres were incubated at both 42°C and 43°C in comparison to the control group.
Conclusion: Altogether, we found that heat-induced upregulated expression of gp96 in CSCs enriched mammospheres from breast tumor tissue might be used as a complementary procedure to generate more immunogenic antigens in immunotherapy settings.

Keywords

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7-34.
  2. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet. 2019; 394: 1159-1168.
  3. Naser Al Deen N, Nassar F, Nasr R, Talhouk R. Cross-roads to drug resistance and metastasis in breast cancer: miRNAs regulatory function and biomarker capability. Adv Exp Med Biol. 2019; 1152: 335-364.
  4. Sousa B, Ribeiro AS, Paredes J. Heterogeneity and plasticity of breast cancer stem cells. Adv Exp Med Biol. 2019; 1139: 83-103.
  5. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3: 730-737.
  6. Capp JP. Cancer Stem Cells: from historical roots to a new perspective. J Oncol. 2019; 2019: 5189232.
  7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100(7): 3983-3988.
  8. Cammareri P LY, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells. Methods Cell Biol. 2008; 86: 311-324.
  9. Chen T, Yang K, Yu J, Meng W, Yuan D, Bi F, et al. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res. 2012; 22(1): 248-258.
  10. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017; 23(10): 1124-1134.
  11. Abbaszadegan MR, Bagheri V, Razavi MS, Momtazi AA, Sahebkar A, Gholamin M. Isolation, identification, and characterization of cancer stem cells: a review. J Cell Physiol. 2017; 232(8): 2008-2018.
  12. Li R, Qian J, Zhang W, Fu W, Du J, Jiang H, et al. Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma. Br J Haematol. 2014; 166(5): 690-701.
  13. Shevtsov M, Pitkin E, Ischenko A, Stangl S, Khachatryan W, Galibin O, et al. Ex vivo Hsp70-activated nk cells in combination with pd-1 inhibition significantly increase overall survival in preclinical models of glioblastoma and lung cancer. Front Immunol. 2019; 10: 454.
  14. Zhang Y, Zhang Y, Chen J, Liu Y, Luo W. Dendritic-tumor fusion cells derived heat shock protein70-peptide complex has enhanced immunogenicity. PLoS One. 2015; 10: e0126075.
  15. Wu BX, Hong F, Zhang Y, Ansa-Addo E, Li Z. GRP94/gp96 in Cancer: Biology, Structure, Immunology, and Drug Development. Adv Cancer Res. 2016; 129: 165-90.
  16. Wang Y, Sedlacek AL, Pawaria S, Xu H, Scott MJ, Binder RJ. Cutting Edge: the heat shock protein gp96 activates inflammasomesignaling platforms in APCs. J Immunol. 2018; 201(8): 2209-2214.
  17. Strbo N, Garcia-Soto A, Schreiber TH, Podack ER. Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. Immunol Res. 2013; 57(1-3): 311-25.
  18. Wang S, Fan H, Li Y, Zheng H, Li X, Li C, et al. CD133 epitope vaccine with gp96 as adjuvant elicits an antitumor T cell response against leukemia. Sheng Wu Gong Cheng Xue Bao. 2017; 33(6): 1006-1017.
  19. Sanmamed MF, Chen L. A Paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018; 175(2): 313-326.
  20. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17(10): 1253-1270
  21. Ruan S, Liu Y, Tang X, Yang Z, Huang J, Li X, et al. HER-2 status and its clinicopathologic significance in breast cancer in patients from southwest China: re-evaluation of correlation between results from FISH and IHC. Int J Clin Exp Pathol. 2017; 10(7): 7270-7276.
  22. Park HS, Han HJ, Lee S, Kim GM, Park S, Choi YA, et al. Detection of circulating tumor cells in breast cancer patients using cytokeratin- 19 real-time RT-PCR. Yonsei Med J. 2017; 58(1): 19-26.
  23. Simsek BC, Turk BA, Ozen F, Tuzcu M, Kanters M. Investigation of telomerase activity and apoptosis on invasive ductal carcinoma of the breast using immunohistochemical and Western blot methods. Eur Rev Med Pharma Sci. 2015; 19(16): 3089-3099.
  24. Zhao W, Li Y, and Zhang X. Stemness-related markers in cancer. Cancer Transl Med. 2017; 3(3): 87-95.
  25. Amaral RLF, Miranda M, Marcato PD, Swiech K. Comparative analysis of 3D bladder tumor spheroids obtained by forced floating and hanging drop methods for drug screening. Front Physiol. 2017; 8: 605.
  26. Weiswald LB, Bellet D, Dangles-Marie V. Spherical cancer models in tumor biology. Neoplasia. 2015; 17: 1-15.
  27. Akbarzadeh M, Maroufi NF, Tazehkand AP, Akbarzadeh M, Bastani S, Safdari R, et al. Current approaches in identification and isolation of cancer stem cells. J Cell Physiol. 2019.
  28. Novak D, Huser L, Elton JJ, Umansky V, Altevogt P, Utikal J. SOX2 in development and cancer biology. Semin Cancer Biol. 2019.
  29. Gawlik-Rzemieniewska N, Bednarek I. The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells. Cancer Biol Ther. 2016; 17(1): 1-10.
  30. Villodre ES, Kipper FC, Pereira MB, Lenz G. Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis. Cancer Treat Rev. 2016; 51: 1-9.
  31. De Maio A, Vazquez D. Extracellular heat shock proteins: a new location, a new function. Shock. 2013; 40(4): 239-246.
  32. Kelly M, McNeel D, Fisch P, Malkovsky M. Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. Immunol Lett. 2018; 193: 1-10.
  33. Yun CW, Kim HJ, Lim JH, Lee SH. Heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy. Cells. 2019; 9(1): 60.
  34. Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother. 2006; 55: 329-338.
  35. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol. 2005; 6: 593-599.
  36. Ansa-Addo EA, Thaxton J, Hong F, Wu BX, Zhang Y, Fugle CW, et al. Clients and oncogenic roles of molecular chaperone gp96/ grp94. Curr Top Med Chem. 2016; 16(25): 2765-2778.
  37. Hoter A, El-Sabban ME, Naim HY. The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci. 2018; 19(9): 2560.
  38. Madersbacher S, Groble M, Kramer G, Dirnhofer S, Steiner GE, Marberger M. Regulation of heat shock protein 27 expression of prostatic cells in response to heat treatment. Prostate. 1998; 37(3): 174-181.
  39. Schueller G PP, Friedl J, Stift A, Dubsky P, Bachleitner-Hofmann T, Jakesz R, et al. Heat treatment of hepatocellular carcinoma cells: increased levels of heat shock proteins 70 and 90 correlate with cellular necrosis. Anticancer Res. 2001; 21(1A): 295-300.
  40. Zaimoku R, Miyashita T, Tajima H, Takamura H, Harashima AI, Munesue S, et al. Monitoring of heat shock response and phenotypic changes in hepatocellular carcinoma after heat treatment. Anticancer Res. 2019; 39(10): 5393-5401.

Files

Cited by

Share

How to cite

Statistics